The published literature on pediatric gender medicine contains no randomized controlled trials, according to assessments cited in a review of evidence and best practices for pediatric gender dysphoria.
November 19, 2025
high
finding
Statement about the absence of randomized controlled trials in the evidence base for medical treatments for minors with gender dysphoria.
Medical interventions for pediatric gender dysphoria—commonly described as puberty blockers, cross-sex hormones, and gender-affirming surgeries—are associated in the literature with potential risks including infertility/sterility, sexual dysfunction, impaired bone density accrual, adverse cognitive impacts, cardiovascular disease and metabolic disorders, psychiatric disorders, surgical complications, and regret.
November 19, 2025
high
finding
List of potential adverse outcomes associated with medical and surgical treatments for minors with gender dysphoria as noted in evidence reviews.